Market Place
Sourcing Support
Roivant Units Reach $2.25B Patent Settlement With Moderna
03 Mar 2026 //
GLOBENEWSWIRE
Arbutus Reports Q3 2025 Financials And Corporate Update
13 Nov 2025 //
GLOBENEWSWIRE
Arbutus To Present Four Abstracts At AASLD Liver Meeting 2025
07 Oct 2025 //
GLOBENEWSWIRE
Arbutus Reports Q1 2025 Financial Results and Corporate Update
14 May 2025 //
GLOBENEWSWIRE
Arbutus Downsizes to `Core Team` by Laying Off Over Half Staff
28 Mar 2025 //
BIOSPACE
Arbutus Reports Q4 2024 Financial Results and Corporate Update
27 Mar 2025 //
GLOBENEWSWIRE
Genevant, Arbutus File Global Patent Cases Against Moderna
03 Mar 2025 //
GLOBENEWSWIRE
Roivant Announces Resignation and Replacement of Arbutus Board
25 Feb 2025 //
GLOBENEWSWIRE
Arbutus Provides 2025 Corporate and Financial Update
13 Jan 2025 //
GLOBENEWSWIRE
Whitefort Sends Letter to Arbutus Biopharma Board
03 Dec 2024 //
BUSINESSWIRE
Arbutus to Participate in HC Wainwright @ Home Virtual Chat
26 Nov 2024 //
GLOBENEWSWIRE
Arbutus’ Imdusiran Achieves Functional Cure in cHBV with Interferon
15 Nov 2024 //
GLOBENEWSWIRE
Arbutus to Present at Jefferies London Healthcare Conference
14 Nov 2024 //
GLOBENEWSWIRE
Arbutus Reports Q3 2024 Financial Results & Corporate Update
06 Nov 2024 //
GLOBENEWSWIRE
Arbutus Q3 2024 Financial Results and Corporate Update
23 Oct 2024 //
GLOBENEWSWIRE
Arbutus Announces Abstracts Highlighting Imdusiran Data Accepted
15 Oct 2024 //
GLOBENEWSWIRE
Arbutus to Present at H.C. Wainwright Viral Hepatitis Conference
01 Oct 2024 //
GLOBENEWSWIRE
Arbutus to Participate in Two Upcoming Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Arbutus Reports Q2 2024 Results And Corporate Update
01 Aug 2024 //
GLOBENEWSWIRE
UniQure, Arbutus, HilleVax Announce Layoffs
01 Aug 2024 //
FIERCE BIOTECH
Arbutus To Report Q2 2024 Results And Provide Corporate Update
18 Jul 2024 //
GLOBENEWSWIRE
Arbutus: Imdusiran+IFN Achieves Sustained HBsAg Undetectability
05 Jun 2024 //
GLOBENEWSWIRE
Arbutus to Present Imdusiran Data at EASL Congress 2024
22 May 2024 //
GLOBENEWSWIRE
Whitefort Publishes Open Letter On Maximizing Arbutus Value
17 May 2024 //
BUSINESSWIRE
Arbutus CSO Michael Sofia Retiring Dec 31, 2024
02 May 2024 //
GLOBENEWSWIRE
Arbutus Reports First Quarter 2024 Financial Results
02 May 2024 //
GLOBENEWSWIRE
Arbutus Announces Claim Ruling in its Ongoing Patent Infring Against Moderna
04 Apr 2024 //
GLOBENEWSWIRE
Moderna shares fall after judge sides with Arbutus in patent fight
04 Apr 2024 //
REUTERS
Arbutus to Participate in Two Upcoming Investor Conferences
08 Mar 2024 //
GLOBENEWSWIRE
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
07 Nov 2023 //
GLOBENEWSWIRE
Arbutus Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Arbutus to Present at H.C. Wainwright 4th Annual HBV Virtual Conference
18 Oct 2023 //
GLOBENEWSWIRE
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD
11 Oct 2023 //
GLOBENEWSWIRE
Arbutus to Participate in Two Upcoming Investor Conferences
07 Sep 2023 //
GLOBENEWSWIRE
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
03 Aug 2023 //
GLOBENEWSWIRE
Arbutus to Report Q2 2023 Financial Results and Provide Corporate Update
20 Jul 2023 //
GLOBENEWSWIRE
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
12 Jul 2023 //
GLOBENEWSWIRE
Arbutus Appoints Two New Executives
10 Jul 2023 //
GLOBENEWSWIRE
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple
21 Jun 2023 //
GLOBENEWSWIRE
Arbutus previews Hepatitis B RNAi treatment data
07 Jun 2023 //
CLINICAL TRIALS ARENA
Arbutus to Present at Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Arbutus to Present at JMP Securities Life Sciences Conference
09 May 2023 //
GLOBENEWSWIRE
Arbutus to Report 1Q 2023 FYR and Provide Corporate Update
20 Apr 2023 //
GLOBENEWSWIRE
Arbutus Doses First Subject in PI Trial with its Oral RNA Destabilizer, AB-161
16 Mar 2023 //
GLOBENEWSWIRE
Arbutus Presents AB-343 Data at International Conference on Antiviral Research
14 Mar 2023 //
GLOBENEWSWIRE
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
Arbutus to Participate in Three Upcoming Investor Conferences
06 Feb 2023 //
GLOBENEWSWIRE
Arbutus Announces Resignation of Board Member
27 Jan 2023 //
GLOBENEWSWIRE
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729
13 Dec 2022 //
GLOBENEWSWIRE
Drugs up for sale, on the shelf in biotech pipeline clear-outs
09 Nov 2022 //
FIERCEBIOTECH
Moderna`s motion to dismiss patent suit denied by federal judge
04 Nov 2022 //
FIERCEPHARMA
Arbutus Presents AB-729 Data & AB-101 Preclinical Data at AASLD
01 Nov 2022 //
GLOBENEWSWIRE
Arbutus Announces Presentations with Data from AB-729 and AB-101
31 Oct 2022 //
GLOBENEWSWIRE
Arbutus to Report Q3 2022 Financial Results and Provide Corporate Update
26 Oct 2022 //
GLOBENEWSWIRE
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
30 Sep 2022 //
GLOBENEWSWIRE
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
22 Sep 2022 //
GLOBENEWSWIRE
Arbutus to Participate in September Investor Conferences
06 Sep 2022 //
GLOBENEWSWIRE
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729
30 Aug 2022 //
GLOBENEWSWIRE
